3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Neoplasms
2
Stroke
1
Recurrence
1
Ovarian Neoplasms
1
Neurologic Manifestations
1
Melanoma
1
Margins of Excision
1
Malignant Solid Neoplasm
1
Malignant Female Reproductive System Neoplasm
1
Inflammatory Breast Neoplasms
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Communication
1
Colorectal Neoplasms
1
Caregiver Burden
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Brain Neoplasms
1
Brain Injuries, Traumatic
1
Brain Injuries
1
Advanced Malignant Solid Neoplasm
1
Interventions
Bevacizumab
19
Paclitaxel
16
Carboplatin
12
pembrolizumab
11
liposomal doxorubicin
10
Cyclophosphamide
9
Specimen Handling
8
Gemcitabine
8
olaparib
7
fludarabine
7
Topotecan
7
Magnetic Resonance Spectroscopy
7
Taxes
5
Immunoglobulin G
5
Fulvestrant
5
Disulfides
5
niraparib
4
Oxaliplatin
4
Nivolumab
4
Biopsy
4
trastuzumab deruxtecan
3
palbociclib
3
mirvetuximab soravtansine
3
aldesleukin
3
Leucovorin
3
Fluorouracil
3
1-dodecylpyridoxal
3
ulixertinib
2
nilotinib
2
ipatasertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Palliative Care
×
30 days
×
Clear all
NCT07617753
2026-06-01
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled